CHEK2-mutation in Dutch breast cancer families: Expanding genetic testing for breast cancer;CHEK2-mutatie in Nederlandse borstkankerfamilies: Uit breiding van de genetische di agn ostiek op borstk anker

Nederlands Tijdschrift voor Geneeskunde

Volumn 159, Issue 45, 2015, Pages

  Adank, Muriel A ^a   Hes, Frederik J ^b   Van Zelst Stams, Wendy A G ^c   Van Den Tol, M Petrousjka ^a   Seynaeve, Caroline ^d   Oosterwijk, Jan C ^e  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d ERASMUS MC CANCER INSTITUTE   (Netherlands)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BREAST CANCER; CANCER RISK; CHEK2 GENE; GENE; GENE MUTATION; GENETIC SCREENING; HETEROZYGOSITY; HUMAN; MAMMOGRAPHY; NETHERLANDS; ONCOGENE; TUMOR SUPPRESSOR GENE; BREAST NEOPLASMS; FEMALE; GENE DELETION; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; MUTATION; PROGNOSIS; RISK FACTOR;

CHECKPOINT KINASE 2; CHEK2 PROTEIN, HUMAN;

BREAST NEOPLASMS; CHECKPOINT KINASE 2; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; GENOTYPE; HUMANS; MAMMOGRAPHY; MUTATION; NETHERLANDS; PROGNOSIS; RISK FACTORS; SEQUENCE DELETION;

EID: 84946600046     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Lodder-van der Vlies D, Droogh-de Greve KE, de Win JLM, et al. Verwijzing voor mammogram vaak niet volgens richtlijn. Ned Tijdschr Geneeskd. 2015; 159: A8636.
2. Ponder BA, Antoniou A, Dunning A, Easton DF, Pharoah PD. Polygenic inherited predisposition to breast cancer. Cold Spring Harb Symp Quant Biol. 2005; 70: 35-41.
3. Wooster R, Weber BL. Breast and ovarian cancer. N Engl J Med. 2003; 348: 2339-47.
4. Foulkes WD. Inherited susceptibility to common cancers. N Engl J Med. 2008; 359: 2143-53.
5. Meijers-Heijboer H, van den Ouweland A, Klijn J, et al; CHEK2-Breast Cancer Consortium. Low-penetrance susceptibility to breast cancer due to CHEK2(∗)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet. 2002; 31: 55-9.
6. CHEK2 Breast Cancer Case-Control Consortium. CHEK2∗1100delC and susceptibility to breast cancer: a collaborative analysis involving 10, 860 breast cancer cases and 9, 065 controls from 10 studies. Am J Hum Genet. 2004; 74: 1175-82.
7. Weischer M, Bojesen SE, Ellervik C, Tybjaerg-Hansen A, Nordestgaard BG. CHEK2∗1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26, 000 patient cases and 27, 000 controls. J Clin Oncol. 2008; 26: 542-8.
8. Narod SA. Testing for CHEK2 in the cancer genetics clinic: ready for prime time? Clin Genet. 2010; 78: 1-7.
9. Schutte M, Seal S, Barfoot R, et al; Breast Cancer Linkage Consortium. Variants in CHEK2 other than 1100delC do not make a major contribution to breast cancer susceptibility. Am J Hum Genet. 2003; 72: 1023-8.
10. Fletcher O, Johnson N, Dos Santos Silva I, et al. Family history, genetic testing, and clinical risk prediction: pooled analysis of CHEK2 1100delC in 1, 828 bilateral breast cancers and 7, 030 controls. Cancer Epidemiol Biomarkers Prev. 2009; 18: 230-4.
11. Cybulski C, Wokołorczyk D, Jakubowska A, et al. Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer. J Clin Oncol. 2011; 29: 3747-52.
12. Johnson N, Fletcher O, Naceur-Lombardelli C, dos Santos Silva I, Ashworth A, Peto J. Interaction between CHEK2∗1100delC and other low-penetrance breast-cancer susceptibility genes: a familial study. Lancet. 2005; 366: 1554-7.
13. Adank MA, Verhoef S, Oldenburg RA, et al. Excess breast cancer risk in first degree relatives of CHEK2 1100delC positive familial breast cancer cases. Eur J Cancer. 2013; 49: 1993-9.
14. Oldenburg RA, Kroeze-Jansema K, Kraan J, et al. The CHEK2∗1100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families. Cancer Res. 2003; 63: 8153-7.
15. Zhang S, Phelan CM, Zhang P, et al. Frequency of the CHEK2 1100delC mutation among women with breast cancer: an international study. Cancer Res. 2008; 68: 2154-7.
16. Weischer M, Bojesen SE, Tybjaerg-Hansen A, Axelsson CK, Nordestgaard BG. Increased risk of breast cancer associated with CHEK2∗1100delC. J Clin Oncol. 2007; 25: 57-63. .
17. De Bock GH, Schutte M, Krol-Warmerdam EM, et al. Tumour characteristics and prognosis of breast cancer patients carrying the germline CHEK2∗1100delC variant. J Med Genet. 2004; 41: 731-5.
18. Kriege M, Hollestelle A, Jager A, et al. Survival and contralateral breast cancer in CHEK2 1100delC breast cancer patients: impact of adjuvant chemotherapy. Br J Cancer. 2014; 111: 1004-13.
19. Broeks A, de Witte L, Nooijen A, et al. Excess risk for contralateral breast cancer in CHEK2∗1100delC germline mutation carriers. Breast Cancer Res Treat. 2004; 83: 91-3.
20. Mellemkjaer L, Dahl C, Olsen JH, et al; WECARE Study Collaborative Group. Risk for contralateral breast cancer among carriers of the CHEK2∗1100delC mutation in the WECARE Study. Br J Cancer. 2008; 98: 728-33.
21. Evans DG, Ahmed M, Bayliss S, Howard E, Lalloo F, Wallace A. BRCA1, BRCA2 and CHEK2 c.1100 delC mutations in patients with double primaries of the breasts and/or ovaries. J Med Genet. 2010; 47: 561-6.
22. Rhiem K, Engel C, Graeser M, et al. The risk of contralateral breast cancer in patients from BRCA1/2 negative high risk families as compared to patients from BRCA1 or BRCA2 positive families: a retrospective cohort study. Breast Cancer Res. 2012; 14: R156.
23. Weischer M, Nordestgaard BG, Pharoah P, et al. CHEK2∗1100delC heterozygosity in women with breast cancer associated with early death, breast cancer-specific death, and increased risk of a second breast cancer. J Clin Oncol. 2012; 30: 4308-16.
24. Schmidt MK, Tollenaar RA, de Kemp SR, et al. Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2∗1100delC germline mutation. J Clin Oncol. 2007; 25: 64-9.
25. Adank MA, Jonker MA, Kluijt I, et al. CHEK2∗1100delC homozygosity is associated with a high breast cancer risk in women. J Med Genet. 2011; 48: 860-3.
26. Huijts PEA, Hollestelle A, Balliu B, et al. CHEK2∗1100delC homozygosity in the Netherlands - prevalence and risk of breast and lung cancer. Eur J Hum Genet. 2014; 22: 46-51.